Affinage

CYRIB

CYFIP-related Rac1 interactor B · UniProt Q9NUQ9

Length
324 aa
Mass
36.7 kDa
Annotated
2026-06-09
33 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CYRI-B (FAM49B) is an evolutionarily conserved regulator of actin-based cell behaviors that acts as a local brake on Rac1-driven cytoskeletal dynamics (PMID:30250061, PMID:39453414). It directly binds active, GTP-loaded Rac1 through its DUF1394 domain, the same fold shared with the CYFIP subunit of the Scar/WAVE complex, and competes with Scar/WAVE for Rac1, thereby limiting Arp2/3-driven actin polymerization at the cell edge to restrict lamellipodia size and duration (PMID:30250061, PMID:33217330). Crystal structures of CYRI-B alone and bound to Rac1(Q61L) define a unique Rac1-effector interface, a conformational 'Ratchet' subdomain that moves upon binding, and an autoinhibitory homo-/heterodimerization mode with its paralogue CYRI-A (PMID:33021503, PMID:33217330). Through this Rac1-restraining activity CYRI-B governs macropinocytosis and receptor trafficking — controlling internalization of α5β1 integrin and the chemoattractant receptor LPAR1 (PMID:34165494, PMID:38712822) — and suppresses phagocytosis downstream of CEACAM3 by limiting Rac-GTP loading and PAK phosphorylation (PMID:37264948). It also shapes focal adhesion maturation and microtubule-mediated adhesion turnover via control of polymerized actin and ERC1 localization (PMID:41277545), and dampens Rac1-dependent signaling outputs including T cell receptor signaling, where loss in mice causes excessive thymocyte negative selection and depletion of peripheral and gut T cell subsets (PMID:29632189, PMID:39158947). CYRI-B abundance and activity are themselves regulated: by miR-22-mediated suppression of its 3′-UTR (PMID:35131594), by TRIM21-mediated ubiquitin-proteasome degradation that LANCL1 counteracts (PMID:37540188), and by AEP cleavage at N169/N170 that converts the intact inhibitor into Rac1-activating fragments promoting smooth-muscle migration and atherosclerosis (PMID:40567229). Across cancer contexts CYRI-B loss generally de-represses Rac1 and downstream pathways such as Rac1-STAT3 to enhance migration, invasion and EMT (PMID:36584745, PMID:38712822).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2017 Medium

    Established the first cellular role and localization for FAM49B by placing it at mitochondria as a restraint on mitochondrial fission and ROS, before its Rac1-centered function was known.

    Evidence Mitochondrial fractionation, siRNA knockdown, ROS and proliferation/invasion assays in pancreatic cancer cells

    PMID:29059164

    Open questions at the time
    • Does not connect mitochondrial localization to Rac1 binding
    • Single lab, no reciprocal localization validation
    • Mechanism linking FAM49B to the fission machinery unresolved
  2. 2018 High

    Defined FAM49B/CYRI-B as a direct binder of active Rac1 that suppresses Rac1-driven actin assembly and signaling, answering what its molecular partner and activity are.

    Evidence Co-IP, CRISPR disruption of the FAM49B-Rac interaction, PAK phosphorylation and CD69 induction assays; independently, pulldown plus optogenetic Rac1 activation and live imaging of lamellipodia

    PMID:29632189 PMID:30250061

    Open questions at the time
    • Did not resolve the structural interface
    • Did not establish how CYRI-B competes with Scar/WAVE at atomic detail
  3. 2019 High

    Localized CYRI-B's Rac1 binding to the DUF1394 domain and showed its restraint of macropinocytosis, phagocytosis and migration confers host defense, while an unbiased screen confirmed CYRI as a new class of active-Rac1 interactor.

    Evidence In vivo mutagenesis screen, domain-mapped binding assays, macropinocytosis/phagocytosis/migration assays, Salmonella infection models; separate mass-spectrometry active-Rac1 interactome

    PMID:31285585 PMID:31413787

    Open questions at the time
    • MS screen single lab, not independently replicated within the study
    • How SopE selectively neutralizes CYRI not structurally defined
  4. 2020 High

    Provided the structural basis for CYRI-Rac1 recognition and revealed a dimerization-based autoinhibition layer, explaining how CYRI-B competes with Scar/WAVE.

    Evidence X-ray crystallography of whale shark CYRI-B and of CYRI-BΔN apo and Rac1(Q61L)-bound forms, structure-guided mutagenesis, competition binding assays

    PMID:33021503 PMID:33217330

    Open questions at the time
    • Full-length protein including N-terminal helix not crystallized
    • Regulation of the dimer-to-monomer transition in cells not established
  5. 2021 High

    Connected CYRI proteins to receptor trafficking, showing PI3K/RAC1-dependent recruitment to nascent macropinosomes and control of integrin internalization, linking the actin brake to membrane uptake.

    Evidence Live-cell imaging of CYRI-A recruitment, PI3K/RAC1 inhibition, dual CYRI-A/B depletion, flow cytometry of surface integrin, invasion and 3D growth assays

    PMID:34165494

    Open questions at the time
    • Relative contributions of CYRI-A versus CYRI-B not fully separated
    • Cargo selectivity of CYRI-dependent macropinocytosis incomplete
  6. 2022 Medium

    Identified upstream and downstream control nodes: miR-22 transcriptional suppression of FAM49B and its Rac1-dependent inhibition of TRAF6/IKK inflammatory signaling, and collagen/DDR1-mediated suppression feeding into Rac1-STAT3 in cancer.

    Evidence Dual luciferase reporter for miR-22 targeting, IKK phosphorylation and in vivo Rac1 interference in hepatic I/R; siRNA knockdown, Rac1-STAT3 western blots, DDR1 blocking and xenograft in gastric cancer

    PMID:35131594 PMID:36584745

    Open questions at the time
    • Both single-lab studies
    • Direct biochemical link between FAM49B and TRAF6/IKK not shown
    • How DDR1 signaling lowers CYRI-B expression unresolved
  7. 2023 High

    Showed CYRI-B protein levels are set by a TRIM21 ubiquitin-degradation axis opposed by LANCL1, and confirmed its role as a negative regulator of CEACAM3-driven phagocytosis via Rac-GTP/PAK.

    Evidence MS, Co-IP of FAM49B-TRIM21, ubiquitination and proteasome-inhibitor assays, ROS measurement; genome-wide CRISPR screen, clonal CYRI-B KO, Rac-GTP/PAK readouts and complementation rescue

    PMID:37264948 PMID:37540188

    Open questions at the time
    • LANCL1/TRIM21 axis single lab
    • TRIM21 ubiquitination site on FAM49B not mapped
  8. 2024 High

    In vivo genetics consolidated CYRI-B as a physiological Rac1 brake across tissues — receptor (LPAR1) trafficking and metastasis control in pancreatic cancer, TCR signal tuning in thymocyte selection, and WAVE-dependent lamellipodia restraint in platelets and Drosophila.

    Evidence Cyrib deletion in KRAS/p53 pancreatic model with receptor internalization/chemotaxis/ERK-JNK readouts; Fam49b-KO mice thymic flow cytometry; platelet Cyfip1/Fam49b single and double KO epistasis; Drosophila loss-of-function wound healing, macrophage and border cell assays

    PMID:38391912 PMID:38712822 PMID:39158947 PMID:39453414

    Open questions at the time
    • Stage-specific dual role of CYRI-B in early proliferation versus late metastasis incompletely mechanistically defined
    • Cell-type-specific contributions of dimerization/autoinhibition in vivo not tested
  9. 2025 High

    Revealed proteolytic conversion of CYRI-B function and expanded its mechanistic reach: AEP cleavage produces Rac1-activating fragments, and new partners (NEK9, ELAVL1) and adhesion/microtubule control diversify its outputs.

    Evidence AEP cleavage-site MS/mutagenesis, AEP-KO mouse, fragment overexpression and Rac1 activity/VSMC migration/atherosclerosis assays; BioID-paxillin focal adhesion screen with imaging; Co-IP of NEK9 and ELAVL1 with downstream c-Myc/Rab10-TLR4 readouts; microglial knockdown phenotyping

    PMID:34645466 PMID:39780509 PMID:40567229 PMID:41277545 PMID:41419490

    Open questions at the time
    • NEK9 and ELAVL1 interactions are single-lab Co-IP with limited mechanistic depth
    • Whether AEP-fragment switch operates outside vascular smooth muscle unknown
    • Microglial phenotypes not mechanistically tied to Rac1 or WAVE competition

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CYRI-B integrates its multiple regulatory inputs (dimerization autoinhibition, miR-22, TRIM21/LANCL1, AEP cleavage) into a coherent threshold that determines when and where Rac1 is locally restrained remains unresolved.
  • No unified model relating CYRI-B abundance, conformation and localization to lamellipodial output
  • Structural basis of the AEP-generated activating fragments' Rac1 binding not solved
  • Reconciliation of mitochondrial localization with the cytoskeletal Rac1 function unaddressed

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 3 GO:0008092 cytoskeletal protein binding 2 GO:0140313 molecular sequestering activity 2
Localization
GO:0005856 cytoskeleton 2 GO:0005886 plasma membrane 2 GO:0005739 mitochondrion 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-5653656 Vesicle-mediated transport 3 R-HSA-1430728 Metabolism 2 R-HSA-168256 Immune System 2
Partners
CYRI-AELAVL1LANCL1NEK9RAC1TRIM21

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2018 FAM49B (CYRI-B) directly interacts with the active (GTP-bound) form of the small GTPase Rac1, and genetic disruption of this interaction compromises FAM49B function in suppressing T cell activation, PAK phosphorylation, and actin assembly. Co-immunoprecipitation, CRISPR-based genetic disruption of FAM49B-Rac interaction, CD69 induction assay, PAK phosphorylation assay Proceedings of the National Academy of Sciences of the United States of America High 29632189
2018 CYRI-B binds activated Rac1 via its DUF1394 domain (shared with CYFIP), inhibits Scar/WAVE-induced actin polymerization at the cell edge, and thereby restricts lamellipodia size and duration. CYRI-depleted cells display broad, stable lamellipodia enriched in Scar/WAVE, while CYRI overexpression suppresses Scar/WAVE recruitment. Protein pulldown/Co-IP for Rac1 binding, optogenetic Rac1 activation, live-cell imaging of protrusion dynamics, CYRI depletion and overexpression with Scar/WAVE localization readout Nature cell biology High 30250061
2017 FAM49B localizes to mitochondria and regulates mitochondrial fission; silencing FAM49B in pancreatic cancer cells increases mitochondrial fission and mitochondrial ROS generation. Mitochondrial fractionation/localization, ROS measurement, siRNA knockdown, proliferation and invasion assays Oncogene Medium 29059164
2019 CYRI-B (FAM49B) binds RAC1 through its conserved DUF1394 domain and negatively regulates RAC1 signaling, thereby attenuating macropinocytosis, phagocytosis, and cell migration to confer host resistance to Salmonella infection. The bacterial effector SopE (a RAC1 activator) selectively targets CYRI to dampen its function. In vivo genome-wide mutagenesis screen, protein-protein binding assays for RAC1 interaction, macropinocytosis assay, phagocytosis assay, cell migration assay, bacterial infection models Nature microbiology High 31285585
2020 Crystal structure of whale shark CYRI-B reveals it comprises three distinct α-helical subdomains and is highly structurally related to the DUF1394-containing domain of CYFIP proteins, establishing the structural basis for Rac1 binding. X-ray crystallography Acta crystallographica. Section D, Structural biology High 33021503
2020 Crystal structures of CYRI-B (lacking N-terminal helix) alone and in complex with active Rac1(Q61L) reveal: (1) a unique Rac1-effector interface in the N-terminal subdomain of CYRI-B, (2) conformational changes in a C-terminal 'Ratchet' subdomain upon Rac1 binding, and (3) that CYRI-A and CYRI-B can form autoinhibited homo- or heterodimers, providing an additional layer of regulation. CYRI-B directly competes with Scar/WAVE complex for Rac1 binding. X-ray crystallography of CYRI-BΔN and CYRI-BΔN:Rac1Q61L complex, structure-guided mutagenesis, competition binding assays Structure (London, England : 1993) High 33217330
2021 CYRI-A (the paralogue of CYRI-B) is transiently recruited to nascent macropinosomes in a PI3K- and RAC1-dependent manner, preceding RAB5A recruitment. CYRI-A regulates macropinosome formation and α5β1 integrin internalization; depletion of both CYRI-A and CYRI-B enhances surface integrin expression, migration, invasion, and anchorage-independent growth. Live-cell imaging of CYRI-A recruitment, PI3K and RAC1 inhibition, siRNA depletion, integrin surface expression by flow cytometry, invasion assays, 3D growth assays The Journal of cell biology High 34165494
2019 Mass spectrometry-based unbiased screen for interactors of active Rac1 confirmed CYRI interaction with GTP-bound Rac1, supporting CYRI as a new class of Rac1 interactors. Mass spectrometry interactome screen with active Rac1 mutant as bait Communicative & integrative biology Medium 31413787
2022 miR-22 directly targets the 3′-UTR of FAM49B (confirmed by dual luciferase reporter assay), reducing FAM49B expression. FAM49B inhibits TRAF6/IKK signaling and downstream pro-inflammatory responses in hepatic ischemia/reperfusion injury in a Rac1-dependent manner (interference of Rac1 reversed FAM49B inhibition effects). Dual luciferase reporter assay for miR-22 targeting, miR-22 inhibition experiments, IKK phosphorylation measurement, in vivo Rac1 interference Molecular immunology Medium 35131594
2023 LANCL1 stabilizes FAM49B protein by blocking FAM49B interaction with the E3 ubiquitin ligase TRIM21, thereby protecting FAM49B from ubiquitin-proteasome degradation. The LANCL1-FAM49B axis suppresses Rac1-NADPH oxidase-driven ROS production. Mass spectrometry (FAM49B identified as LANCL1 binding partner), co-immunoprecipitation for FAM49B-TRIM21 interaction, ubiquitination assay, ROS measurement, proteasome inhibitor experiments Hepatology (Baltimore, Md.) Medium 37540188
2022 Knockdown of CYRI-B in gastric cancer cells activates the Rac1-STAT3 pathway, promoting migration, invasion, and EMT. Collagen type I reduces CYRI-B expression via the collagen receptor DDR1. CYRI-B siRNA knockdown, western blotting for Rac1-STAT3 pathway activation, migration and invasion assays, DDR1 collagen receptor blocking experiments, in vivo xenograft Experimental cell research Medium 36584745
2023 CYRI-B is a negative regulator of CEACAM3-mediated phagocytosis: CYRI-B knockout in HL-60 cells enhances Rac-GTP loading and PAK phosphorylation downstream of CEACAM3, resulting in increased phagocytosis of bacteria. Complementation with CYRI-B reverts the knockout phenotype. Genome-wide CRISPR/Cas9 screen, clonal CYRI-B knockout generation, Rac-GTP loading assay, PAK phosphorylation western blot, phagocytosis assay with fluorescent bacteria, genetic complementation Journal of cell science High 37264948
2024 CYRI-B mediates macropinocytic uptake of lysophosphatidic acid receptor 1 (LPAR1); loss of CYRI-B in pancreatic cancer cells impairs LPAR1 internalization, reducing chemotactic responses to lysophosphatidic acid and inhibiting metastasis. In early disease, CYRI-B loss leads to enhanced ERK and JNK-induced proliferation in precancerous lesions. Cyrib gene deletion in mouse KRAS/p53-driven pancreatic cancer model, receptor internalization assay, chemotaxis assay, ERK/JNK phosphorylation, in vivo tumor progression analysis eLife High 38712822
2024 Fam49b dampens TCR signal strength in thymocytes to prevent excessive negative selection; Fam49b-KO mice show excessive negative selection of DP thymocytes, impaired survival of SP thymocytes, and significant reductions in CD4 and CD8 SP thymocytes and peripheral T cells. Large proportions of TCRγδ+ and CD8αα+TCRαβ+ gut intraepithelial T lymphocytes were absent in Fam49b-KO mice. Novel Fam49b-KO mouse generation, flow cytometric analysis of thymic subsets, TCR signaling assays in primary cells eLife High 39158947
2024 In platelets, FAM49b negatively regulates lamellipodia formation and migration: Fam49b-/- platelets spread faster with larger areas on fibrinogen, are more prone to polarization and migration, and these phenotypes depend on functional WAVE complex (double Cyfip1/Fam49b KO eliminates lamellipodia, phenocopying Cyfip1 KO alone). Platelet-specific Fam49b-/-, Cyfip1-/-, and Cyfip1/Fam49b-/- mouse models, platelet spreading assay on fibrinogen, migration assay, structured micropatterns Cells High 38391912
2024 In Drosophila, CYRI acts as a molecular brake on the Rac-WRC-Arp2/3 pathway: loss of CYRI accelerates epidermal wound healing and enhances lamellipodial spreading in macrophages; CYRI also limits invasive border cell cluster migration by controlling cluster cohesion. Drosophila CYRI loss-of-function genetics, wound healing assay, live imaging of macrophage lamellipodia, border cell migration assay The Journal of cell biology High 39453414
2025 FAM49B is cleaved by the cysteine protease AEP (asparagine endopeptidase) at residues N169 and N170, generating two fragments FAM49B(1-169) and FAM49B(171-324). While full-length FAM49B inhibits VSMC migration, the fragments bind Rac1 and increase its activity, inducing actin polymerization and promoting VSMC migration and atherosclerotic plaque formation. Mass spectrometry fragment identification, AEP cleavage site mutagenesis (N169/N170), AEP knockout mouse, adenoviral overexpression of full-length vs. fragment FAM49B in VSMCs, Rac1 activity assay, VSMC migration assay, in vivo atherosclerosis models Arteriosclerosis, thrombosis, and vascular biology High 40567229
2025 CYRI-B loss leads to accelerated focal adhesion maturation, formation of excessively large focal adhesions, accumulation of polymerized actin in stress fibres that acts as a barrier to microtubule targeting, and depletion of the integrin internalization mediator ERC1 from adhesion sites. This reveals a connection between CYRI-B-controlled lamellipodia dynamics and microtubule-mediated adhesion turnover. CYRI-B siRNA depletion, BioID proximity screen with paxillin as bait, focal adhesion morphometry, microtubule and actin imaging, ERC1 localization assay Journal of cell science High 41277545
2025 FAM49B interacts with NEK9 and promotes NEK9-Thr210 phosphorylation; FAM49B knockdown reduces NEK9 phosphorylation and enhances K48-linked ubiquitination and degradation of c-Myc, suppressing CRC proliferation and migration. Co-immunoprecipitation of FAM49B-NEK9 interaction, western blot for NEK9-Thr210 phosphorylation, c-Myc ubiquitination assay (K48-specific), FAM49B knockdown with NEK9 rescue experiments, cell cycle analysis BioFactors (Oxford, England) Medium 39780509
2021 FAM49B interacts with ELAVL1 protein; endogenous FAM49B co-immunoprecipitates with ELAVL1 in breast cancer cells, and FAM49B positively regulates Rab10 and TLR4 expression by stabilizing ELAVL1 protein, thereby activating the ELAVL1/Rab10/TLR4/NF-κB signaling axis. Co-immunoprecipitation of FAM49B-ELAVL1, FAM49B knockdown with Rab10/TLR4 western blot, microarray analysis, xenograft model Cancer cell international Medium 34645466
2025 Downregulation of FAM49B in microglia (as modeled in human and murine microglial cells) leads to alterations in cytoskeletal maintenance, migration, surface adherence, energy homeostasis, autophagy, and increased microglial activation/inflammatory response. FAM49B knockdown in human and murine microglia, cytoskeletal assays, migration assay, metabolic assays, inflammatory cytokine measurement npj aging Medium 41419490

Source papers

Stage 0 corpus · 33 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation. Proceedings of the National Academy of Sciences of the United States of America 96 29632189
2018 Fam49/CYRI interacts with Rac1 and locally suppresses protrusions. Nature cell biology 70 30250061
2017 FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. Oncogene 58 29059164
2019 CYRI/FAM49B negatively regulates RAC1-driven cytoskeletal remodelling and protects against bacterial infection. Nature microbiology 44 31285585
2020 TASP1 Promotes Gallbladder Cancer Cell Proliferation and Metastasis by Up-regulating FAM49B via PI3K/AKT Pathway. International journal of biological sciences 31 32071545
2022 FAM49B, restrained by miR-22, relieved hepatic ischemia/reperfusion injury by inhibiting TRAF6/IKK signaling pathway in a Rac1-dependent manner. Molecular immunology 28 35131594
2021 CYRI-A limits invasive migration through macropinosome formation and integrin uptake regulation. The Journal of cell biology 27 34165494
2021 FAM49B promotes breast cancer proliferation, metastasis, and chemoresistance by stabilizing ELAVL1 protein and regulating downstream Rab10/TLR4 pathway. Cancer cell international 23 34645466
2020 The novel fish miRNA pol-miR-novel_171 and its target gene FAM49B play a critical role in apoptosis and bacterial infection. Developmental and comparative immunology 22 31958496
2023 LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress. Hepatology (Baltimore, Md.) 17 37540188
2020 Structure of CYRI-B (FAM49B), a key regulator of cellular actin assembly. Acta crystallographica. Section D, Structural biology 14 33021503
2009 Thalassobacillus cyri sp. nov., a moderately halophilic Gram-positive bacterium from a hypersaline lake. International journal of systematic and evolutionary microbiology 13 19622638
2020 Structural Basis of CYRI-B Direct Competition with Scar/WAVE Complex for Rac1. Structure (London, England : 1993) 12 33217330
2024 CYRI-B-mediated macropinocytosis drives metastasis via lysophosphatidic acid receptor uptake. eLife 8 38712822
2022 GOLM1 and FAM49B: Potential Biomarkers in HNSCC Based on Bioinformatics and Immunohistochemical Analysis. International journal of molecular sciences 8 36499755
2019 CYRI/ Fam49 Proteins Represent a New Class of Rac1 Interactors. Communicative & integrative biology 8 31413787
2018 Characterization of CyrI, the hydroxylase involved in the last step of cylindrospermopsin biosynthesis: Binding studies, site-directed mutagenesis and stereoselectivity. Archives of biochemistry and biophysics 7 29653078
2024 CYRI controls epidermal wound closure and cohesion of invasive border cell cluster in Drosophila. The Journal of cell biology 6 39453414
2022 Downregulation of CYRI-B promotes migration, invasion and EMT by activating the Rac1-STAT3 pathway in gastric cancer. Experimental cell research 6 36584745
2023 CYRI proteins: controllers of actin dynamics in the cellular 'eat vs walk' decision. Biochemical Society transactions 5 36892409
2024 Differential Role of the RAC1-Binding Proteins FAM49b (CYRI-B) and CYFIP1 in Platelets. Cells 3 38391912
2022 Characterization and Functional Study of FAM49B Reveals Its Effect on Cell Proliferation in HEK293T Cells. Genes 3 35205432
2025 FAM49B drives colorectal cancer progression by stabilizing c-Myc through NEK9 phosphorylation. BioFactors (Oxford, England) 2 39780509
2024 Fam49b dampens TCR signal strength to regulate survival of positively selected thymocytes and peripheral T cells. eLife 2 39158947
2023 A genome-wide genetic screen identifies CYRI-B as a negative regulator of CEACAM3-mediated phagocytosis. Journal of cell science 2 37264948
2025 Single-cell and spatial transcriptomics integration reveals FAM49B promotes tumor-associated macrophages polarization in colorectal cancer via the MK pathway. Frontiers in immunology 1 41246334
2025 Circ_0011446 Regulates Intramuscular Adipocyte Differentiation in Goats via the miR-27a-5p/FAM49B Axis. International journal of molecular sciences 0 40076914
2025 Regulation of Exosomal miR-320d/FAM49B Axis by Guanylate Binding Protein 5 Promotes Cell Growth and Tumor Progression in Oral Squamous Cell Carcinoma. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 0 40097332
2025 FAM49B Fragmentation by Asparagine Endopeptidase Promotes Vascular Smooth Muscle Cell Migration in Atherogenesis. Arteriosclerosis, thrombosis, and vascular biology 0 40567229
2025 FAM49B suppresses ovarian cancer cell growth through regulating MAPK signaling. American journal of cancer research 0 41113986
2025 CYRI-B loss promotes enlarged mature focal adhesions and restricts microtubule and ERC1 access to the cell leading edge. Journal of cell science 0 41277545
2025 Age-related nigral downregulation of the Parkinson's risk factor FAM49B primes human microglia for inflammaging. npj aging 0 41419490
2021 Dynamic Rac1 inhibition by CYRI helps cells drink, but stops them from driving. The Journal of cell biology 0 34402856

Missed literature

Know a paper Affinage missed for CYRIB? Flag it for the maintainers and the community.

No submissions yet.